Baseline patient characteristics (n = 31) of antineutrophil cytoplasmic antibodies (ANCA) associated vasculitis patients in remission at the time of endogenous thrombin generation (ETP) potential measurement.
| Characteristic | n |
|---|---|
| Age, yrs, ± SD | 51.4 ± 15.4 |
| Male/female | 16/15 |
| Diagnosis | |
| GPA (%) | 29 (93.5) |
| MPA (%) | 1 (3.2) |
| EGPA (%) | 1 (3.2) |
| ANCA subtype | |
| MPO-ANCA (%) | 7 (22.6) |
| PR3-ANCA (%) | 24 (77.4) |
| Disease duration, yrs (range) | 6.6 (3.1–9.0) |
| Immunosuppressive medication† | |
| None (%) | 8 (25.8) |
| Prednisone with azathioprine (%) | 8 (25.8) |
| Azathioprine alone (%) | 2 (6.4) |
| MMF (%) | 2 (6.4) |
| Prednisone with MMF (%) | 3 (9.7) |
| Prednisone with methotrexate (%) | 5 (16.1) |
| Prednisone alone (%) | 3 (9.7) |
| VTE before study (%) | 5 (16.1) |
| Anticoagulant use (%) | 4 (12.9) |
| C-reactive protein, mg/l, (range) | 3.9 (2.7–7.6) |
| D-dimers, ng/ml (range) | 291 (180–463) |
| BVAS | 0 |
| Serum creatinine, μmol/l (range) | 84 (71–97) |
| Leukocyte counts, cells × 109/l (range) | 6.3 (5.4–7.9) |
| Platelet counts, cells × 109/l (range) | 274 (206–309) |
| IgG anti-CMV antibodies present (%) | 18 (58.1) |
↵† Median amount of prednisone use daily was 5 mg (range 2 mg to 17.5 mg). GPA: granulomatous polyangiitis; MPA: microscopic polyangiitis; EGPA: eosinophilic granulomatosis with polyangiitis; MPO: myeloperoxidase; PR3: proteinase-3; MMF: mycophenolate mofetil; VTE: venous thromboembolism; BVAS: Birmingham Vasculitis Activity Score; CMV: cytomegalovirus; HDL: high-density lipoprotein; LDL: low-density lipoprotein; Ig: immunoglobulin.